By employing experiments on cell culture and mouse models, we identified that scEMC10 suppressed muscle glucose uptake via inhibition of both GLUT4 translocation and expression, which involve multiple signaling pathways, and inhibition of scEMC10 may be a therapeutic strategy for type 2 diabetes via enhancement of muscle glucose uptake. Here, SLC2A4 is linked to type 2 diabetes mellitus.